Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic <i>BRAF</i> Wild-Type Anaplastic Thyroid CarcinomaSarah Hamidi, Ramona Dadu, Mark Zafereo et al.|Thyroid|2026Cited by 2